Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment

NCT02370017 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: ANKL(Ex vivo-expanded NK cell enriched lymphocytes)

Sponsor

The Catholic University of Korea